AMAG Pharmaceuticals Inc

Find Ratings Reports
AMAG : NASDAQ : Health Care
$23.35 up 0.35 | 1.52%
Today's Range: 22.65 - 23.55
Avg. Daily Volume: 1243000.0
01/17/17 - 4:14 PM ET

Financial Analysis


AMAG PHARMACEUTICALS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. AMAG PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.08 which clearly shows the ability to cover any short-term cash needs. AMAG managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 1.95% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)143.7896.15
EBITDA ($mil)71.7729.31
EBIT ($mil)44.0412.34
Net Income ($mil)16.2-20.58


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)614.07473.63
Total Assets ($mil)2527.652554.41
Total Debt ($mil)987.811005.16
Equity ($mil)937.95919.96


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin89.8430.48
EBITDA Margin49.9130.48
Operating Margin30.6312.83
Sales Turnover0.190.14
Return on Assets0.66.59
Return on Equity1.6218.32
Debt Q3 FY16 Q3 FY15
Current Ratio2.242.46
Debt/Capital0.510.52
Interest Expense18.3114.22
Interest Coverage2.410.87


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)34.2134.7
Div / share0.00.0
EPS0.43-0.62
Book value / share27.4226.51
Institutional Own % n/a n/a
Avg Daily Volume1229396.0776751.0

Valuation


HOLD. AMAG PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 34.33 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 25.49. For additional comparison, its price-to-book ratio of 0.82 indicates a significant discount versus the S&P 500 average of 2.84 and a significant discount versus the industry average of 11.43. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AMAG 57.69 Peers 34.33   AMAG 3.48 Peers 27.22

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

AMAG is trading at a significant premium to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

AMAG is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
AMAG 3.20 Peers 24.82   AMAG 0.10 Peers 0.41

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

AMAG is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

AMAG trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AMAG 0.82 Peers 11.43   AMAG -92.59 Peers 3.61

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AMAG is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, AMAG is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AMAG 1.57 Peers 136.62   AMAG 34.85 Peers 532.92

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AMAG is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

AMAG significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades